New Lilly Injection Cuts 47 Pounds in Trial

Eli Lilly reported on Wednesday that its experimental drug, retatrutide, produced more than double the weight loss of the highest available dose of Ozempic. The company shared these findings from a phase 3 clinical trial involving over 1,000 adults with type 2 diabetes. The results suggest a major shift in how pharmaceutical companies approach appetite suppression and metabolic health.

Participants taking the 12mg dose of retatrutide lost an average of 47.4 pounds over 80 weeks. Those on the 9mg dose lost 44.3 pounds on average. By comparison, patients on the maximum 2mg dose of Ozempic lost 20.9 pounds during the same period. The new medication also showed superior effects on heart health markers, including cholesterol levels and blood pressure.

Retatrutide works differently than current market leaders because it mimics three distinct hunger-regulating hormones. It targets GLP-1, GIP, and glucagon. Most existing drugs, such as Ozempic and Wegovy from Novo Nordisk, only mimic GLP-1. Mounjaro and Zepbound, also from Eli Lilly, mimic GLP-1 and GIP. The addition of glucagon is a key differentiator, as this hormone promotes fat burning even when the body is at rest.

The trial also measured changes in A1C, a marker for diabetes risk. Retatrutide lowered A1C by 2.2%, while Ozempic lowered it by 1.8%. Eli Lilly stated it plans to file for U.S. Food and Drug Administration approval in early 2027. Its rival, Novo Nordisk, has a competing experimental drug called CagriSema that seeks approval by the end of this year.

Neither retatrutide nor CagriSema has received full FDA approval yet. The agency warned that any versions of these drugs found online are from the black market and should not be consumed. Currently, Ozempic and Mounjaro are approved for type 2 diabetes, while Wegovy and Zepbound are approved for treating overweight and obesity.

Health care providers advise patients to discuss these options before starting treatment. The new data places pressure on existing competitors as the market for weight loss medications continues to expand with more potent options.